Company: AEMD
Filing Date: 2025-08-20
Form Type: S-1
Source: 0001683168-25-006352
Chunk: 70

Company: AETHLON MEDICAL INC
Filing Date: 2025-08-20
Form: S-1
Chunk 70
---
 or in part, any proposed purchase of common stock to be made directly or through agents. We will not receive any of the
proceeds from this Inducement Offering. Upon any exercise of the warrants by payment of cash, however, we will receive the exercise price
of the Inducement Warrants.

| 41 |

The Selling Securityholders also
may resell all or a portion of the shares in open market transactions in reliance upon Rule 144 under the Securities Act, provided that
it meets the criteria and conforms to the requirements of that rule.

The Selling Securityholders and
any underwriters, broker-dealers or agents that participate in the sale of the common stock or interests therein may be “underwriters”
within the meaning of Section 2(a)(11) of the Securities Act. Any discounts, commissions, concessions or profit they earn on any resale
of the shares may be underwriting discounts and commissions under the Securities Act. Any Selling Securityholder who is an “underwriter”
within the meaning of Section 2(a)(11) of the Securities Act will be subject to the prospectus delivery requirements of the Securities
Act.

To the extent required, the shares
of our common stock to be sold, the name of the Selling Securityholder, the respective purchase prices and public offering prices, the
names of any agents, dealer or underwriter, and any applicable commissions or discounts with respect to a particular offer will be set
forth in an accompanying prospectus supplement or, if appropriate, a post-effective amendment to the registration statement that includes
this prospectus.

In order to comply with the securities
laws of certain states, if applicable, the common stock may be sold in these jurisdictions only through registered or licensed brokers
or dealers. In addition, in some states, the common stock may not be sold unless (i) it has been registered or qualified for sale or (ii)
an exemption from registration or qualification requirements is available and is complied with.

We have advised the Selling Securityholders
that the anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of shares in the market and to the activities
of the Selling Securityholders and their affiliates. In addition, to the extent applicable we will make copies of this prospectus (as
it may be supplemented or amended from time to time) available to the Selling Securityholders for the purpose of satisfying the prospectus
delivery requirements of the Securities Act. The Selling Securityholders may indemnify any broker-dealer that participates in transactions